Dianthus Therapeutics Surges After Positive Trial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 05 2024
0mins
Should l Buy DNTH?
Source: Business Insider
Dianthus Therapeutics Inc. saw its stock price increase by 7.83%, reaching a 52-week high, following the announcement of an early 'go' decision for its drug claseprubart in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) program.
The company's decision was based on promising interim results from the trial, where over 20 responders were confirmed out of 40 participants, achieving a response rate of 50% or greater. Analysts responded positively, with Truist raising its price target from $63 to $110 and H.C. Wainwright increasing its target from $47 to $130, reflecting heightened confidence in the drug's prospects.
This surge in stock price indicates strong market optimism and investor interest in Dianthus, especially as the company continues to make significant strides in its clinical programs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DNTH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DNTH
Wall Street analysts forecast DNTH stock price to fall
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 85.840
Low
46.00
Averages
77.00
High
125.00
Current: 85.840
Low
46.00
Averages
77.00
High
125.00
About DNTH
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company engaged in designing and delivering monoclonal antibodies with improved selectivity and potency. The Company is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. It is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Dianthus Therapeutics Prices Upsized $625 Million Public Offering
- Upsized Offering: Dianthus Therapeutics announced the upsizing of its public offering from an initially proposed $400 million to $625 million, issuing 7.31 million shares at $81.00 each, reflecting strong market demand for its stock.
- Pre-Funded Warrants: The company is also offering pre-funded warrants for 402,468 shares priced at $80.999 each, with a low exercise price designed to attract more investors, thereby enhancing its fundraising capabilities.
- Clear Use of Proceeds: The expected total proceeds of approximately $625 million will be utilized for advancing clinical and preclinical development, preparing for commercial readiness, and general corporate purposes, indicating a well-defined strategic plan for future growth.
- Underwriters' Option: The underwriters have a 30-day option to purchase an additional 1.16 million shares, which adds flexibility and potential scale to the offering, demonstrating market confidence in the company's future growth prospects.
See More
Dianthus Therapeutics Prices $625 Million Upsized Public Offering
- Upsized Financing: Dianthus Therapeutics is offering 7.31 million shares at $81 each, raising $625 million, expected to close on March 12, 2026, to support multiple programs targeting severe autoimmune and neuromuscular diseases.
- Clinical Trial Advancements: The lead program, Claseprubart, is set to initiate a Phase 3 trial for generalized myasthenia gravis in mid-2026, with topline results anticipated in 2H 2028, highlighting the company's strategic focus on high unmet medical needs.
- Early Clinical Success: Claseprubart achieved an early
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Upgrades and Downgrades: While specific upgrades and downgrades are not detailed, such changes typically have a significant impact on the short-term performance of the affected stocks, prompting investors to pay close attention to these adjustments.
- Market Reaction Expectations: The adjustments in analyst ratings may lead to increased attention on AZO stock, as investors reassess their strategies based on these changes, potentially affecting trading volumes and price fluctuations.
- Source Reliability: The market news and data provided by Benzinga serve as a crucial reference for investors; although it does not offer investment advice, its analyst ratings page provides a comprehensive view of rating changes for informed decision-making.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
- Upgrades and Downgrades: The rating changes include upgrades and downgrades for certain stocks, prompting investors to pay attention to these shifts to assess potential investment opportunities and risks.
- Market Reaction Expectations: Analysts' rating adjustments may lead to short-term volatility in the affected stocks, necessitating investors to closely monitor market dynamics to seize investment opportunities.
- Information Source: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, providing crucial insights for investor decision-making.
See More
Dianthus Therapeutics Launches $400 Million Public Offering
- Offering Size: Dianthus Therapeutics has announced the commencement of a $400 million public offering of common stock, with plans to offer pre-funded warrants to certain investors, indicating the company's proactive approach to capital markets.
- Underwriters' Option: The company expects to grant underwriters a 30-day option to purchase up to an additional $60 million of common stock at the public offering price, a strategy that may enhance demand for its shares in the market.
- Use of Proceeds: The net proceeds from this offering are intended to support clinical and preclinical development, commercial readiness activities, and general corporate purposes, underscoring the company's strategic focus on R&D and market preparedness.
- Stock Price Reaction: Following the announcement of the offering, Dianthus Therapeutics' stock price fell 3.46% in after-hours trading to $76.69, reflecting a cautious market sentiment regarding the offering.
See More
Liquidia and Dianthus See Active Options Trading
- Liquidia Options Volume: Liquidia Corp (Ticker: LQDA) experienced an options trading volume of 9,692 contracts today, equating to approximately 969,200 shares, which represents about 48.1% of its average daily trading volume of 2 million shares over the past month, indicating heightened market interest in its future performance.
- High Call Option Activity: Among LQDA options, the $47.50 strike call option expiring on January 21, 2028, has seen particularly high activity with 3,100 contracts traded today, representing around 310,000 underlying shares, suggesting increased investor expectations for a price rise.
- Dianthus Options Trading: Dianthus Therapeutics Inc (Ticker: DNTH) recorded an options trading volume of 3,379 contracts today, equivalent to approximately 337,900 shares, which is about 48% of its average daily trading volume of 704,415 shares over the past month, reflecting market interest in its potential volatility.
- High Put Option Activity: The $50 strike put option for DNTH, expiring on March 20, 2026, has seen 1,659 contracts traded today, representing approximately 165,900 underlying shares, indicating investor concern regarding potential downside risks.
See More
Dianthus Therapeutics Prices Upsized $625 Million Public Offering
- Upsized Offering: Dianthus Therapeutics announced the upsizing of its public offering from an initially proposed $400 million to $625 million, issuing 7.31 million shares at $81.00 each, reflecting strong market demand for its stock.
- Pre-Funded Warrants: The company is also offering pre-funded warrants for 402,468 shares priced at $80.999 each, with a low exercise price designed to attract more investors, thereby enhancing its fundraising capabilities.
- Clear Use of Proceeds: The expected total proceeds of approximately $625 million will be utilized for advancing clinical and preclinical development, preparing for commercial readiness, and general corporate purposes, indicating a well-defined strategic plan for future growth.
- Underwriters' Option: The underwriters have a 30-day option to purchase an additional 1.16 million shares, which adds flexibility and potential scale to the offering, demonstrating market confidence in the company's future growth prospects.
See More
Dianthus Therapeutics Prices $625 Million Upsized Public Offering
- Upsized Financing: Dianthus Therapeutics is offering 7.31 million shares at $81 each, raising $625 million, expected to close on March 12, 2026, to support multiple programs targeting severe autoimmune and neuromuscular diseases.
- Clinical Trial Advancements: The lead program, Claseprubart, is set to initiate a Phase 3 trial for generalized myasthenia gravis in mid-2026, with topline results anticipated in 2H 2028, highlighting the company's strategic focus on high unmet medical needs.
- Early Clinical Success: Claseprubart achieved an early
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Upgrades and Downgrades: While specific upgrades and downgrades are not detailed, such changes typically have a significant impact on the short-term performance of the affected stocks, prompting investors to pay close attention to these adjustments.
- Market Reaction Expectations: The adjustments in analyst ratings may lead to increased attention on AZO stock, as investors reassess their strategies based on these changes, potentially affecting trading volumes and price fluctuations.
- Source Reliability: The market news and data provided by Benzinga serve as a crucial reference for investors; although it does not offer investment advice, its analyst ratings page provides a comprehensive view of rating changes for informed decision-making.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
- Upgrades and Downgrades: The rating changes include upgrades and downgrades for certain stocks, prompting investors to pay attention to these shifts to assess potential investment opportunities and risks.
- Market Reaction Expectations: Analysts' rating adjustments may lead to short-term volatility in the affected stocks, necessitating investors to closely monitor market dynamics to seize investment opportunities.
- Information Source: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, providing crucial insights for investor decision-making.
See More
Dianthus Therapeutics Launches $400 Million Public Offering
- Offering Size: Dianthus Therapeutics has announced the commencement of a $400 million public offering of common stock, with plans to offer pre-funded warrants to certain investors, indicating the company's proactive approach to capital markets.
- Underwriters' Option: The company expects to grant underwriters a 30-day option to purchase up to an additional $60 million of common stock at the public offering price, a strategy that may enhance demand for its shares in the market.
- Use of Proceeds: The net proceeds from this offering are intended to support clinical and preclinical development, commercial readiness activities, and general corporate purposes, underscoring the company's strategic focus on R&D and market preparedness.
- Stock Price Reaction: Following the announcement of the offering, Dianthus Therapeutics' stock price fell 3.46% in after-hours trading to $76.69, reflecting a cautious market sentiment regarding the offering.
See More
Liquidia and Dianthus See Active Options Trading
- Liquidia Options Volume: Liquidia Corp (Ticker: LQDA) experienced an options trading volume of 9,692 contracts today, equating to approximately 969,200 shares, which represents about 48.1% of its average daily trading volume of 2 million shares over the past month, indicating heightened market interest in its future performance.
- High Call Option Activity: Among LQDA options, the $47.50 strike call option expiring on January 21, 2028, has seen particularly high activity with 3,100 contracts traded today, representing around 310,000 underlying shares, suggesting increased investor expectations for a price rise.
- Dianthus Options Trading: Dianthus Therapeutics Inc (Ticker: DNTH) recorded an options trading volume of 3,379 contracts today, equivalent to approximately 337,900 shares, which is about 48% of its average daily trading volume of 704,415 shares over the past month, reflecting market interest in its potential volatility.
- High Put Option Activity: The $50 strike put option for DNTH, expiring on March 20, 2026, has seen 1,659 contracts traded today, representing approximately 165,900 underlying shares, indicating investor concern regarding potential downside risks.
See More
